

Denis Moro-Sibilot

List of Publications by Citations

Source: <https://exaly.com/author-pdf/850257/denis-moro-sibilot-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

87
papers

7,932
citations

34
h-index

89
g-index

93
ext. papers

9,549
ext. citations

7.1
avg, IF

5.03
L-index

#	Paper	IF	Citations
87	Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. <i>New England Journal of Medicine</i> , 2013 , 368, 2385-94	59.2	2594
86	Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. <i>Lancet, The</i> , 2016 , 387, 1405-1414	40	549
85	Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1997-2003	2.2	453
84	Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. <i>Journal of Clinical Oncology</i> , 2016 , 34, 661-8	2.2	441
83	Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2002 , 20, 247-53 ^{2.2}	2.2	428
82	Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. <i>Lancet, The</i> , 2011 , 378, 1079-88	40	411
81	Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers. <i>Science Translational Medicine</i> , 2013 , 5, 186ra66	17.5	258
80	Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. <i>Lancet Oncology, The</i> , 2019 , 20, 239-253	21.7	238
79	Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2019 , 20, 1655-1669	21.7	215
78	Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 1233-1243	8.9	188
77	CD74-NRG1 fusions in lung adenocarcinoma. <i>Cancer Discovery</i> , 2014 , 4, 415-22	24.4	173
76	Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study. <i>Journal of Thoracic Oncology</i> , 2012 , 7, 348-54	8.9	170
75	Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors. <i>Nature Communications</i> , 2018 , 9, 1048	17.4	152
74	Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2167-72	2.2	143
73	On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas. <i>Lung Cancer</i> , 2014 , 83, 168-73	5.9	93
72	Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study. <i>Oncotarget</i> , 2017 , 8, 21903-21917	3.3	90
71	Use of intensive care in patients with nonresectable lung cancer. <i>Chest</i> , 2011 , 139, 101-8	5.3	68

70	High TUBB3 expression, an independent prognostic marker in patients with early non-small cell lung cancer treated by preoperative chemotherapy, is regulated by K-Ras signaling pathway. <i>Molecular Cancer Therapeutics</i> , 2012 , 11, 1203-13	6.1	66
69	Endovascular treatment of malignant superior vena cava syndrome: results and predictive factors of clinical efficacy. <i>CardioVascular and Interventional Radiology</i> , 2013 , 36, 140-9	2.7	59
68	Outcomes and resource use of non-small cell lung cancer (NSCLC) patients treated with first-line platinum-based chemotherapy across Europe: FRAME prospective observational study. <i>Lung Cancer</i> , 2015 , 88, 215-22	5.9	48
67	Disease flare after treatment discontinuation in a patient with EML4-ALK lung cancer and acquired resistance to crizotinib. <i>Journal of Thoracic Oncology</i> , 2012 , 7, e1-2	8.9	48
66	A Brief Report of Transformation From NSCLC to SCLC: Molecular and Therapeutic Characteristics. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 130-134	8.9	47
65	BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers. <i>European Respiratory Journal</i> , 2015 , 45, 1403-14	13.6	43
64	IFCT-0401 Trial: a phase II study of gefitinib administered as first-line treatment in advanced adenocarcinoma with bronchioloalveolar carcinoma subtype. <i>Journal of Thoracic Oncology</i> , 2009 , 4, 1126-35	8.9	43
63	An apoptosis methylation prognostic signature for early lung cancer in the IFCT-0002 trial. <i>Clinical Cancer Research</i> , 2012 , 18, 2976-86	12.9	42
62	Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 963-73	8.9	41
61	Non-small cell lung cancer patients with brain metastases treated with first-line platinum-doublet chemotherapy: Analysis from the European FRAME study. <i>Lung Cancer</i> , 2015 , 90, 427-32	5.9	39
60	Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs crizotinib (CZ) in untreated advanced ALK+ NSCLC.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9043-9043	2.2	39
59	Adequacy of CT-guided biopsies with histomolecular subtyping of pulmonary adenocarcinomas: influence of ATS/ERS/IASLC guidelines. <i>Lung Cancer</i> , 2013 , 82, 69-75	5.9	38
58	Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma. <i>Journal of Pathology</i> , 2011 , 225, 83-95	9.4	38
57	ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer. <i>Lung Cancer</i> , 2018 , 116, 15-24	5.9	35
56	Osteoblastic reaction in non-small cell lung carcinoma and its association to epidermal growth factor receptor tyrosine kinase inhibitors response and prolonged survival. <i>Journal of Thoracic Oncology</i> , 2010 , 5, 491-6	8.9	35
55	Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort. <i>Clinical Lung Cancer</i> , 2019 , 20, e564-e575	4.9	34
54	Lung squamous cell carcinomas with basaloid histology represent a specific molecular entity. <i>Clinical Cancer Research</i> , 2014 , 20, 5777-86	12.9	34
53	Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (IFCT-0301 study). <i>Lung Cancer</i> , 2010 , 70, 301-7	5.9	34

52	Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus. <i>Lung Cancer</i> , 2015 , 87, 89-95	5.9	33
51	Prognostic value of health-related quality of life for overall survival in elderly non-small-cell lung cancer patients. <i>European Journal of Cancer</i> , 2016 , 52, 120-8	7.5	32
50	c-MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid Carcinomas. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 1962-1967	8.9	26
49	Expression of candidate tumor suppressor gene ING2 is lost in non-small cell lung carcinoma. <i>Lung Cancer</i> , 2010 , 69, 180-6	5.9	24
48	Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer.. <i>Nature Medicine</i> , 2022 ,	50.5	23
47	Prognostic impact of paraneoplastic cushing's syndrome in small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2014 , 9, 497-505	8.9	22
46	Selection criteria for intensive care unit referral of lung cancer patients: a pilot study. <i>European Respiratory Journal</i> , 2015 , 45, 491-500	13.6	18
45	Influence of histology and biomarkers on first-line treatment of advanced non-small cell lung cancer in routine care setting: baseline results of an observational study (FRAME). <i>Lung Cancer</i> , 2012 , 78, 263-9	5.9	17
44	Patients with advanced lung cancer harboring oncogenic mutations should be admitted to intensive care units. <i>Intensive Care Medicine</i> , 2015 , 41, 164-5	14.5	15
43	Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study. <i>European Journal of Cancer</i> , 2020 , 131, 27-36	7.5	15
42	Immunohistochemistry evaluation of biomarker expression in non-small cell lung cancer (Pharmacogenoscan study). <i>Lung Cancer</i> , 2014 , 83, 182-8	5.9	15
41	Outcomes in recurrent small-cell lung cancer after one to four chemotherapy lines: a retrospective study of 300 patients. <i>Lung Cancer</i> , 2012 , 78, 112-20	5.9	15
40	Second-line therapy for NSCLC in clinical practice: baseline results of the European SELECTION observational study. <i>Current Medical Research and Opinion</i> , 2010 , 26, 2661-72	2.5	15
39	Trends in response rate and survival in small-cell lung cancer patients between 1997 and 2017. <i>Lung Cancer</i> , 2019 , 131, 122-127	5.9	14
38	MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial. <i>British Journal of Cancer</i> , 2019 , 120, 387-397	8.7	13
37	High MET Overexpression Does Not Predict the presence of MET exon 14 Splice Mutations in NSCLC: Results From the IFCT PREDICT.amm study. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 120-124	8.9	13
36	Cisplatin and carboplatin-based chemotherapy in the first-line treatment of non-small cell lung cancer: Analysis from the European FRAME study. <i>Lung Cancer</i> , 2016 , 92, 35-40	5.9	12
35	MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early-stage lung cancer patients from the IFCT-0002 Phase 3 Trial. <i>Oncotarget</i> , 2017 , 8, 4313-4329	3.3	12

34	Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial. <i>Clinical Cancer Research</i> , 2019 , 25, 5759-5765	12.9	11
33	Cost-effectiveness of , and testing for decision making in advanced nonsmall cell lung carcinoma: the French IFCT-PREDICT.amm study. <i>European Respiratory Journal</i> , 2018 , 51,	13.6	11
32	Randomized Phase II Trial Evaluating Treatment with EGFR-TKI Associated with Antiestrogen in Women with Nonsquamous Advanced-Stage NSCLC: IFCT-1003 LADIE Trial. <i>Clinical Cancer Research</i> , 2020 , 26, 3172-3181	12.9	9
31	Second-line therapy in elderly patients with advanced nonsmall cell lung cancer. <i>European Respiratory Journal</i> , 2014 , 43, 240-9	13.6	9
30	Clinicopathologic Features and Response to Therapy of Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2791-2802	2.2	9
29	ALK-rearranged non-small cell lung cancers: how best to optimize the safety of crizotinib in clinical practice?. <i>Expert Review of Anticancer Therapy</i> , 2015 , 15, 225-33	3.5	8
28	Second-line therapy for non-small cell lung cancer in clinical practice: final results and treatment pathways from the SELECTTION observational study. <i>Current Medical Research and Opinion</i> , 2012 , 28, 1253-62	2.5	8
27	Association between lung cancer somatic mutations and occupational exposure in never-smokers. <i>European Respiratory Journal</i> , 2017 , 50,	13.6	7
26	Professional practice and accessibility to equipment in thoracic oncology. Results of a survey in Rh�nes-Alpes region (France). <i>Bulletin Du Cancer</i> , 2011 ,	2.4	7
25	Are clinical guidelines applied in routine daily practice?: a French regional survey of physicians' clinical practices in lung cancer management (EPOTRA). <i>Clinical Lung Cancer</i> , 2011 , 12, 298-306	4.9	7
24	Chemotherapy effectiveness after first-line gefitinib treatment for advanced lepidic predominant adenocarcinoma (formerly advanced bronchioloalveolar carcinoma): exploratory analysis of the IFCT-0401 trial. <i>Journal of Thoracic Oncology</i> , 2012 , 7, 1423-31	8.9	7
23	Implementing ctDNA Analysis in the Clinic: Challenges and Opportunities in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2020 , 12,	6.6	7
22	Real-life experience of ceritinib in crizotinib-pretreated advanced non-small cell lung cancer patients. <i>ERJ Open Research</i> , 2018 , 4,	3.5	6
21	Similar survival rates with first-line gefitinib, gemcitabine, or docetaxel in a randomized phase II trial in elderly patients with advanced non-small cell lung cancer and a poor performance status (IFCT-0301). <i>Journal of Geriatric Oncology</i> , 2015 , 6, 233-40	3.6	6
20	Patient-reported outcomes in RELAY, a phase 3 trial of ramucirumab plus erlotinib versus placebo plus erlotinib in untreated -mutated metastatic non-small-cell lung cancer. <i>Current Medical Research and Opinion</i> , 2020 , 36, 1667-1675	2.5	6
19	Erlotinib versus carboplatin and paclitaxel in advanced lepidic adenocarcinoma: IFCT-0504. <i>European Respiratory Journal</i> , 2015 , 46, 1440-50	13.6	5
18	Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non-Small-Cell Lung Cancer Harboring Mutations: Results From the IFCT-1703 R2D2 Trial.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101455	2.2	5
17	Randomized phase II trial evaluating treatment with EGFR-TKI versus EGFR-TKI associated with anti-estrogen in women with non-squamous advanced stage NSCLC: IFCT-1003 LADIE trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9097-9097	2.2	5

16	Phase II randomized trial of afatinib with or without cetuximab as first-line treatment for EGFR mutated non-small cell lung cancer (NSCLC) patients (IFCT-1503 ACE-Lung).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9079-9079	2.2	4
15	Percutaneous CT-guided biopsy of lytic bone lesions in patients clinically suspected of lung cancer: Diagnostic performances for pathological diagnosis and molecular testing. <i>Lung Cancer</i> , 2020 , 140, 93-98	5.9	4
14	The TAILOR study: to agree or to disagree?. <i>Lung Cancer</i> , 2014 , 84, 315-6	5.9	3
13	Standards, Options et Recommandations pour le traitement préopératoire des patients atteints d'un cancer bronchique non à petites cellules résectable d'emblée, opérables (mise à jour), rapport abrégé. <i>Oncologie</i> , 2007 , 9, 800-809	1	2
12	Prise en charge oncologique du patient après chimiothérapie adjuvante, surveillance, traitement des rechutes. <i>Oncologie</i> , 2008 , 10, 525-528	1	2
11	Biomarker-driven access to crizotinib in ALK, MET, or ROS1 positive (+) malignancies in adults and children: The French National ACS Program.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2504-2504	2.2	2
10	Impact on health-related quality of life of the addition of bevacizumab to cisplatin-pemetrexed in malignant pleural mesothelioma in the MAPS phase III trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 8505-8505	2.2	2
9	Compliance to regional recommendations for molecular analyses and management of advanced lung cancer patients. <i>Future Oncology</i> , 2019 , 15, 2139-2149	3.6	1
8	Pathologie avancée et défaillances d'organes: outil d'aide à la décision. <i>Medecine Palliative</i> , 2014 , 13, 150-154	0.1	1
7	Pazopanib (P) or placebo in completely resected stage I NSCLC patients: Survival results of the phase II trial IFCT-0703.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 7510-7510	2.2	1
6	Trends in response rate and survival in small cell lung cancer patients between 1997 and 2017.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e20572-e20572	2.2	1
5	Detection of ROS1 translocations in triple-negative lung adenocarcinomas.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 8099-8099	2.2	1
4	Switch maintenance chemotherapy versus observation after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced non-small cell lung cancer: IFCT-1201 MODEL trial. <i>European Journal of Cancer</i> , 2020 , 138, 193-201	7.5	1
3	First-Line Afatinib plus Cetuximab for EGFR-Mutant Non-Small Cell Lung Cancer: Results from the Randomized Phase II IFCT-1503 ACE-Lung Study. <i>Clinical Cancer Research</i> , 2021 , 27, 4168-4176	12.9	1
2	Precision medicine at its best: Prolonged survival in a child presenting a secondary mesothelioma treated with crizotinib. <i>Pediatric Blood and Cancer</i> , 2021 , 68, e28666	3	1
1	Immunotherapy in NSCLC Patients With Brain and Leptomeningeal Metastases.. <i>Frontiers in Oncology</i> , 2022 , 12, 787080	5.3	0